BioLineRx (BLRX) Non-Current Assets (2011 - 2026)

BioLineRx's Non-Current Assets history runs 15 years deep, the most recent figure standing at $17.2 million for Q4 2025.

• In Q4 2025, Non-Current Assets rose 45.94% year-over-year to $17.2 million; the TTM figure through Dec 2025 stood at $17.2 million (up 45.94% YoY), while the FY2025 annual figure was $17.2 million, up 45.94% from the prior year.
• Non-Current Assets for Q4 2025 stood at $17.2 million, up from $11.3 million in the prior quarter.
• The five-year high for Non-Current Assets was $24.4 million in Q4 2022, with the low at $11.3 million in Q3 2025.
• The 5-year median for Non-Current Assets is $23.7 million (2022), against an average of $19.6 million.
• The sharpest annual moves came in 2024 and 2025: Non-Current Assets tumbled 38.07% in 2024, then surged 45.94% in 2025.
• BioLineRx's Non-Current Assets stood at $24.0 million in 2021, then gained by 1.65% to $24.4 million in 2022, then tumbled by 31.34% to $16.7 million in 2023, then retreated by 29.51% to $11.8 million in 2024, then soared by 45.94% to $17.2 million in 2025.
• Business Quant data shows BLRX's Non-Current Assets at $17.2 million in Q4 2025, $11.3 million in Q3 2025, and $11.4 million in Q2 2025.